Review
Copyright ©The Author(s) 2016.
World J Gastroenterol. Aug 28, 2016; 22(32): 7215-7225
Published online Aug 28, 2016. doi: 10.3748/wjg.v22.i32.7215
Table 1 Response and resection rates from trials with first-line chemo/biologic therapy
StudySelectionTreatmentResponseResection
Van Cutsem et al[88] 2009UnselectedBevacizumab + chemotherapy (FOLFOX/FOLFIRI)NA11.8%
6% (R0)
Okines et al[89] 2009UnselectedBevacizumab + Oxaliplatin-based chemotherapy38%6.3%
Wong et al[90] 2011UnselectedBevacizumab + XELOX68%48.0%
Loupakis et al[91] 2013UnselectedBevacizumab + FOLFOXIRI64%15.0%
Martin et al[92] 2014UnselectedBevacizumab + FOLFOX + DEBIRI78%35.0%
Bokemeyer et al[94] 2009KRAS WTCetuximab + FOLFOX57%7.3%
4.7 (R0)
Van Cutsem et al[95] 2011KRAS WTCetuximab + FOLFIRI57%16.0%
7% (R0)
Folprecht et al[22] 2010KRAS WTCetuximab + chemotherapy (FOLFOX/FOLFIRI)68%43.0%
34% (R0)
Garufi et al[96] 2010KRAS WTCetuximab + FOLFOXIRI79%60.0%
Ye et al[97] 2013KRAS WTCetuximab + FOLFOXIRI57%25% (R0)
Köhne et al[100] 2012KRAS WTPanitumumab + FOLFIRI56%15.0%
Douillard et al[101] 2010KRAS WTPanitumumab + FOLFOX57%27.0%
5.2% (R0)
NRAS WTPanitumumab + FOLFOX31.0%